AVR vs. ABOS
AVR (Anteris Technologies Global Corp) and ABOS (Acumen Pharmaceuticals, Inc.) are both stocks. Both are in the Healthcare sector — AVR in Medical Instruments & Supplies, ABOS in Biotechnology. Over the past year, AVR returned 155.37% vs 59.26% for ABOS. Their 0.19 correlation means their historical movements had little consistent relationship.
Performance
AVR vs. ABOS - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, AVR achieves a 57.11% return, which is significantly higher than ABOS's 1.90% return.
AVR
- 1D
- -4.85%
- 1M
- -23.44%
- 6M
- 31.32%
- YTD
- 57.11%
- 1Y
- 155.37%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- 17.84%
ABOS
- 1D
- -0.92%
- 1M
- -21.53%
- 6M
- -17.31%
- YTD
- 1.90%
- 1Y
- 59.26%
- 3Y*
- -33.34%
- 5Y*
- -32.62%
- 10Y*
- —
- ALL TIME*
- -38.33%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $726.33K | $876.46K | $1.09M | |
| $7.66M | $9.78M | $11.23M |
AVR vs. ABOS - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | |
|---|---|---|---|
AVR Anteris Technologies Global Corp | 57.11% | -10.57% | -7.00% |
ABOS Acumen Pharmaceuticals, Inc. | 1.90% | 22.67% | -16.91% |
Correlation
The correlation between AVR and ABOS is 0.20, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.20 |
Correlation (All Time) Calculated using the full available price history since Dec 13, 2024 | 0.19 |
Fundamentals
AVR:
$288.42M
ABOS:
$155.29M
AVR:
-$5.99
ABOS:
-$1.84
AVR:
$1.85M
ABOS:
$0.00
AVR:
$1.38M
ABOS:
-$45.00K
AVR:
-$69.11M
ABOS:
-$111.50M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
AVR vs. ABOS — Risk / Return Rank
AVR
ABOS
AVR vs. ABOS - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Anteris Technologies Global Corp (AVR) and Acumen Pharmaceuticals, Inc. (ABOS). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| AVR | ABOS | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.29 | ||
| Sortino ratioReturn per unit of downside risk | +1.15 | ||
| Omega ratioGain probability vs. loss probability | 1.29 | 1.17 | +0.12 |
| Calmar ratioReturn relative to maximum drawdown | 3.10 | 1.44 | +1.66 |
| Martin ratioReturn relative to average drawdown | 7.98 | 2.70 | +5.28 |
Loading charts...
Drawdowns
AVR vs. ABOS - Drawdown Comparison
The maximum AVR drawdown since its inception was -71.46%, smaller than the maximum ABOS drawdown of -96.41%. Use the drawdown chart below to compare losses from any high point for AVR and ABOS.
Loading charts...
Drawdown Indicators
| AVR | ABOS | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -71.46% | -96.41% | +24.95% |
Max Drawdown (1Y)Largest decline over 1 year | -46.77% | -37.39% | -9.38% |
Max Drawdown (3Y)Largest decline over 3 years | — | -87.66% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -95.22% | — |
Current DrawdownCurrent decline from peak | -25.83% | -91.42% | +65.59% |
Average DrawdownAverage peak-to-trough decline | -34.71% | -81.83% | +47.12% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 18.16% | 19.90% | -1.74% |
Volatility
AVR vs. ABOS - Volatility Comparison
The current volatility for Anteris Technologies Global Corp (AVR) is 14.33%, while Acumen Pharmaceuticals, Inc. (ABOS) has a volatility of 20.29%. This indicates that AVR experiences smaller price fluctuations and is considered to be less risky than ABOS based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| AVR | ABOS | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 14.33% | 20.29% | -5.96% |
Volatility (6M)Calculated over the trailing 6-month period | 41.46% | 51.02% | -9.56% |
Volatility (1Y)Calculated over the trailing 1-year period | 75.80% | 86.16% | -10.36% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 90.18% | 96.91% | -6.73% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 90.18% | 97.00% | -6.82% |
Dividends
AVR vs. ABOS - Dividend Comparison
Neither AVR nor ABOS has paid dividends to shareholders.
Financials
AVR vs. ABOS - Financials Comparison
This section allows you to compare key financial metrics between Anteris Technologies Global Corp and Acumen Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
AVR and ABOS have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ABOS has higher volatility (20.29%) compared to AVR (14.33%). In terms of maximum drawdown, AVR dropped -71.46% vs ABOS's -96.41%.
AVR currently has the higher Sharpe Ratio (1.92 vs 0.63), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for AVR and ABOS
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer